GlobeNewswire: Aurinia Pharmaceuticals Inc. Contains the last 10 of 46 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T05:33:58ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2014/05/15/637034/10082073/en/Aurinia-Reports-First-Quarter-2014-Financial-Results.html?f=22&fvtc=4&fvtv=14073Aurinia Reports First Quarter 2014 Financial Results2014-05-15T23:45:47Z<![CDATA[VICTORIA, British Columbia, May 15, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") has released its financial results for the first quarter ended March 31, 2014.]]>https://www.globenewswire.com/news-release/2014/03/31/622870/10074619/en/Aurinia-Reports-Fourth-Quarter-and-Full-Year-2013-Financial-Results.html?f=22&fvtc=4&fvtv=14073Aurinia Reports Fourth Quarter and Full Year 2013 Financial Results2014-03-31T13:00:00Z<![CDATA[VICTORIA, British Columbia, March 31, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") has released its financial results for the fourth quarter and year ended December 31, 2013.]]>https://www.globenewswire.com/news-release/2014/03/04/615596/10071180/en/Aurinia-to-Present-at-the-26th-Annual-ROTH-Conference.html?f=22&fvtc=4&fvtv=14073Aurinia to Present at the 26th Annual ROTH Conference2014-03-04T21:05:00Z<![CDATA[VICTORIA, British Columbia, March 4, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") today announced that its President and CEO, Stephen Zaruby, will present an overview of the Company at the 26]]>https://www.globenewswire.com/news-release/2014/02/25/613281/10069992/en/Aurinia-to-Present-at-the-34th-Annual-Cowen-Health-Care-Conference.html?f=22&fvtc=4&fvtv=14073Aurinia to Present at the 34th Annual Cowen Health Care Conference2014-02-25T21:30:00Z<![CDATA[VICTORIA, British Columbia, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") today announced that Stephen Zaruby, its President and CEO, will present an overview of the Company and an update on the development of its lead drug candidate, voclosporin, as a therapy for lupus nephritis at the 34th Annual Cowen Health Care Conference on Monday, March 3 at 3:30 p.m. Eastern Time. The conference will be held at the Boston Marriott Copley Place Hotel.]]>https://www.globenewswire.com/news-release/2014/02/19/611398/10068961/en/Aurinia-Announces-Management-Change-and-Grant-of-Stock-Options.html?f=22&fvtc=4&fvtv=14073Aurinia Announces Management Change and Grant of Stock Options2014-02-19T13:00:00Z<![CDATA[VICTORIA, British Columbia, Feb. 19, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") today announced that Dr. Robert Foster has decided to resign from his current position as Chief Scientific Officer, effective immediately, in order to pursue other opportunities. To help facilitate the continued development of its lead product, voclosporin, as an important new therapy for lupus nepthritis, Dr. Foster has agreed to remain available to consult with the Company on an as-needed basis.]]>https://www.globenewswire.com/news-release/2014/02/14/610630/10068529/en/Aurinia-Announces-US-52-Million-Private-Placement.html?f=22&fvtc=4&fvtv=14073Aurinia Announces US$52 Million Private Placement2014-02-14T22:28:20Z<![CDATA[VICTORIA, British Columbia, Feb. 14, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") today announced that it has completed, subject to regulatory approval, a US$52 million private placement (the "Offering"). Aurinia intends to use the net proceeds from the Offering to advance the clinical and nonclinical development of its lead drug candidate, voclosporin, as a therapy for lupus nephritis and for general corporate purposes.]]>https://www.globenewswire.com/news-release/2013/12/09/595468/10060799/en/Aurinia-Announces-Change-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=14073Aurinia Announces Change to Board of Directors2013-12-09T13:30:00Z<![CDATA[VICTORIA, B.C., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") today announced the resignation of Dr. Robert Foster from its Board of Directors. Dr. Foster remains Chief Scientific Officer of the Company.]]>https://www.globenewswire.com/news-release/2013/11/22/591749/10059152/en/Aurinia-Reports-Third-Quarter-2013-Financial-Results.html?f=22&fvtc=4&fvtv=14073Aurinia Reports Third Quarter 2013 Financial Results2013-11-22T00:00:00Z<![CDATA[VICTORIA, British Columbia, Nov. 21, 2013 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (TSX-V:AUP) has released its financial results for the third quarter ended September 30, 2013.]]>https://www.globenewswire.com/news-release/2013/11/06/587266/10056487/en/Aurinia-Appoints-Accomplished-Biotech-and-Pharma-Industry-Veteran-Stephen-W-Zaruby-as-President-CEO.html?f=22&fvtc=4&fvtv=14073Aurinia Appoints Accomplished Biotech and Pharma Industry Veteran, Stephen W. Zaruby, as President & CEO2013-11-06T13:00:00Z<![CDATA[VICTORIA, British Columbia, Nov. 6, 2013 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") today announced the appointment of Stephen W. Zaruby as the Company's President and Chief Executive Officer.]]>https://www.globenewswire.com/news-release/2013/10/22/582467/10053848/en/Aurinia-Announces-Official-Name-Trading-Symbol-Change-and-Implementation-of-Share-Consolidation.html?f=22&fvtc=4&fvtv=14073Aurinia Announces Official Name, Trading Symbol Change and Implementation of Share Consolidation2013-10-22T20:45:00Z<![CDATA[VICTORIA, British Columbia, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX-V:ISA) (the "Company") announced that, further to its press release of September 30, 2013, it has officially changed its name to Aurinia Pharmaceuticals Inc. ("Aurnia") and that its common shares (the "Shares") will be posted for trading on a 50:1 consolidated basis (the "Consolidation") on the TSX Venture Exchange at the opening of market on October 23, 2013 under the new trading symbol "AUP".]]>